July 25, 2017 6:52am

 

Direction must be questioned and at risk for reversal

 

Critical indications ahead of “our” universe’s open!

 

This is a limited-time preview of RegMed Investor's morning call. To get the pre-open briefing, plus daily access of the happenings and realities of “our” universe ……SUBSCRIBE!

Don’t ignore this …

 


 

I know what a company is supposed to look like, be like, and smell like to succeed! Unless you know what happened last week; it is hard to formulate a perspective … for the new day!

 

Slightly higher open expected

Dow futures are UP +0.15% and NASDAQ futures are UP +0.08%

 

U.S. stock index futures pointed to a slightly higher open on Tuesday, as investors awaited a slew of corporate earnings reports and news from an FOMC meeting.

European markets were higher on Tuesday morning as investors monitored earnings and awaited the start of a two-day policy meeting of the Federal Reserve.

Asian indexes closed mostly lower on Tuesday as markets awaited the upcoming Federal Market Open Committee (FOMC) meeting and kept an eye on the dollar amid greater uncertainty over the White House's ability to pass key policy proposals.

 

Data docket: Philadelphia Fed's non-manufacturing business outlook survey is due out at 8.30 a.m. ET, the FHFA Home Price Index and S&P CoreLogic Case-Shiller Home Price Index, both due out around 9.00 a.m. ET. Meanwhile, at 10.00 a.m. ET, consumer confidence data and the Richmond Fed's Survey of Manufacturing Activity are due. On the central bank front, the Federal Open Market Committee (FOMC) is set to begin the first day of its two-day meeting on Tuesday, where the U.S. central bank is expected to look at the current health of the U.S. economy, and contemplate on what they should do next in terms of strategy, interest rates and their balance sheet.

 

Earnings indicator: Biogen and Eli Lilly

In the political sphere, investors will be looking for any news out of the White House, in relation to noise surrounding the Russia-linked scandal and the president's policies.

 

 

The cell therapy sector closed POSITIVE on Monday, last Friday, Thursday, Wednesday and last Tuesday.

The cell therapy sector’s record over the last 5 sessions (of 43 covered companies):

·         Monday closed POSITIVE with 18 decliners, 21 advancers and 4 flats;

·         Friday closed POSITIVE with 16 decliners, 26 advancers and 1 flats;

·         Thursday closed POSITIVE with 11 decliners, 26 advancers and 6 flats;

·         Wednesday closed POSITIVE with 17 decliners, 23 advancers and 3 flats;

·         Tuesday closed POSITIVE with 17 decliners, 24 advancers and 2 flats;

 

 

Henry’omics:

After a few days off and a new treatment regimen, I am close to being back on track!

 “Volume is low as winners and loser jockey for position.

Investors, caught between ETFs and algorithms … should PAUSE to consider how “our” universe of stocks will perform without the taikwinds from market factors as the cell therapy sector trendiest movers may be subject to headwinds!

 

 

Review “the count” - decliners versus gainers:

……. look at the differences in the spreads as percentages migrate……….

·         Monday’s decliners ranged from -0.35% <BSTG> to -56.77% <CYTX> in 18 equities;

Versus

………… look at the positive percentage’s (%) …….

·         Monday’s gainers ranged from +0.61%  <ATHX> to +10.22% <NWBO> in 20 equities;

 

 

You’ve made it to the office, turned on the monitor, having just gotten your coffee and it hits you - what could be today’s trades? 

Watch list:

  • The iShares Nasdaq Biotechnology (IBB) closed flat 0.76% on Monday with the aftermarket was a POSITIVE +0.11% and is indicating a POSITIVE +0.2% in Tuesday’s pre-market;
  • The SPDR S&P Biotech ETF (XBI) closed Monday up +1.2%, and is NOT indicating in Tuesday’s pre-market;
  • The Health Care Select Sector SPDR ETF (XLV) closed down -0.06% Monday, and is NOT indicating in Tuesday’s pre-open;
  • The iShares Russell 2000 (IWM) closed up +0.14% on Monday, and is indicating a POSITIVE +0.015% in Tuesday’s pre-open

 

 

Companies in my headlights:

……..  Staying neutral today …….

 

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Henry’s comments are for informational purposes only and are not a substitute for personalized advice. Consult your advisor about what is best for you.